On 13 June 2025, the European Commission launched the first phase of a pilot project under its COMBINE programme (the pilot project), aiming to streamline the authorisation process for combined studies involving both clinical trials of medicinal products and performance studies of in vitro diagnostic medical devices (IVD) (referred to as combined studies below).

The pilot project represents a significant step towards addressing the complex and fragmented regulatory landscape that sponsors currently face when submitting applications for combined studies across multiple EU countries. Although its practical effectiveness remains to be seen, the pilot project represents a positive development that should facilitate the approval of combined studies in the EU.

The pilot project is the first initiative under the COMBINE programme, with additional projects planned to launch in the coming years.Continue Reading European Commission launches COMBINE pilot to streamline approval of studies involving medicinal products and in vitro diagnostic medical devices

The revised transparency rules governing the transparency of information submitted to the Clinical Trial Information System (CTIS), as adopted by the European Medicines Agency (EMA) on 5 October 2023, will come into effect on 18 June 2024, thesame day thenew CTIS portal will launch. The CTIS, established under the Clinical Trials Regulation (EU) No 536/2014 (CTR), aims at facilitating the information exchange on trials in the European Union (EU). It operates on the principle of public disclosure, with the exception of information relating to personal data and Commercially Confidential Information (CCI).

Preparation is crucial for sponsors conducting clinical trials in the EU as they may need to adapt ongoing trial documentation and future submissions. Our blog post sets out the key changes and provides tips for preparation.Continue Reading Getting Ready for the Upcoming Revised EMA CTIS Transparency Rules